Table 2.

Treatment, response, and survival status of 10 patients

Case	Stagea	Gene Mutation	Anti-tumor	Anti-platelet	Tumor response	Neurological condition	Status		OS (mo.)
1	T3N2M0, IIIB	EGFR 19DEl	Icotinib; Lung radiotherapy	Aspirin, Clopidogrel	PR	Marked Improved	Alive	10
2	T1N2M0, IIIA	NA	No treatment	Clopidogrel	NA	Stable	Dead	7
3	T2N1M1, IVA	EGFR L858R	Gefitinib; Lung radiotherapy	Aspirin	SD	Stable	Alive	27
4	T1N1M0, IIIB	ALK fusion	Ensartinib; Lung radiotherapy	Aspirin, Clopidogrel	PR	Marked Improved	Alive	6
5	T1N3M1, IVB	EGFR L858R	Icotinib; Chemotherapy	Clopidogrel	PR	Marked Improved	Alive	17
6	T2N3M0, IIIB	NA	No treatment	Clopidogrel	NA	Stable	Dead	6
7	T1N2Mo, IIIA	NA	Surgery	Aspirin	NED	Improved	Alive	48
8	T2N2M0, IIIA	Wild Type	Chemotherapy; Surgery	Aspirin, Clopidogrel	PD	Improved	Dead	6
9	T2N1M0, IIIB	NA	No treatment	Aspirin, Clopidogrel	NA	Stable	Dead	12
10	T2N2M0, IIIA	NA	No treatment	Clopidogrel	NA	Stable	Dead	7

^aAccording to the American Joint Committee on Cancer (8th edition)

Abbreviations: OS Overall survival, EGFR Epidermal growth factor receptor, ALK Anaplastic lymphoma kinase, PR Partial response, SD Stable, PD Progressive disease, NED No evidence of disease, NA Not available